TITLE

Mesenchymal Stem Cell 1 (MSC1)-Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis

AUTHOR(S)
Waterman, Ruth S.; Henkle, Sarah L.; Betancourt, Aline M.; Fiorina, Paolo
PUB. DATE
September 2012
SOURCE
PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Currently, there are many promising clinical trials using mesenchymal stem cells (MSCs) in cell-based therapies of numerous diseases. Increasingly, however, there is a concern over the use of MSCs because they home to tumors and can support tumor growth and metastasis. For instance, we established that MSCs in the ovarian tumor microenvironment promoted tumor growth and favored angiogenesis. In parallel studies, we also developed a new approach to induce the conventional mixed pool of MSCs into two uniform but distinct phenotypes we termed MSC1 and MSC2. Methodology/Principal Findings: Here we tested the in vitro and in vivo stability of MSC1 and MSC2 phenotypes as well as their effects on tumor growth and spread. In vitro co-culture of MSC1 with various cancer cells diminished growth in colony forming units and tumor spheroid assays, while conventional MSCs or MSC2 co-culture had the opposite effect in these assays. Co-culture of MSC1 and cancer cells also distinctly affected their migration and invasion potential when compared to MSCs or MSC2 treated samples. The expression of bioactive molecules also differed dramatically among these samples. MSC1-based treatment of established tumors in an immune competent model attenuated tumor growth and metastasis in contrast to MSCs- and MSC2-treated animals in which tumor growth and spread was increased. Also, in contrast to these groups, MSC1-therapy led to less ascites accumulation, increased CD45+leukocytes, decreased collagen deposition, and mast cell degranulation. Conclusion/Significance: These observations indicate that the MSC1 and MSC2 phenotypes may be convenient tools for the discovery of critical components of the tumor stroma. The continued investigation of these cells may help ensure that cell based-therapy is used safely and effectively in human disease.
ACCESSION #
82447386

 

Related Articles

  • Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials. Philippe, Bourin; Luc, Sensebé; Valérie, Planat-Bénard; Jérome, Roncalli; Alessandra, Bura-Rivière; Louis, Casteilla // Stem Cells International;2010, p1 

    Present in numerous tissues, mesenchymal stem cells/multipotent stromal cells (MSCs) can differentiate into different cell types from a mesoderm origin. Their potential has been extended to pluripotency, by their possibility of differentiating into tissues and cells of nonmesodermic origin....

  • Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. Filardo, Giuseppe; Madry, Henning; Jelic, Mislav; Roffi, Alice; Cucchiarini, Magali; Kon, Elizaveta // Knee Surgery, Sports Traumatology, Arthroscopy;Aug2013, Vol. 21 Issue 8, p1717 

    Purpose: The aim of this systematic review is to examine the available clinical evidence in the literature to support mesenchymal stem cell (MSC) treatment strategies in orthopaedics for cartilage defect regeneration. Methods: The research was performed on the PubMed database considering the...

  • Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair. Heinrich, Andrew C.; Patel, Shyam A.; Reddy, Bobby Y.; Milton, Russell; Rameshwar, Pranela // Current Stem Cell Research & Therapy;Jan2009, Vol. 4 Issue 1, p16 

    Stem cell therapy has a place for future application in the treatment of degenerative diseases. Regardless of the origin of the stem cell, when placed within a milieu of inflammatory mediator, they will show varied functions. This review focuses on human mesenchymal stem cells (MSCs) and...

  • The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion. Fenouille, Nina; Tichet, Mélanie; Dufies, Maeva; Pottier, Anaïs; Mogha, Ariane; Soo, Julia K.; Rocchi, Stéphane; Mallavialle, Aude; Galibert, Marie-Dominique; Khammari, Amir; Lacour, Jean-Philippe; Ballotti, Robert; Deckert, Marcel; Tartare-Deckert, Sophie // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    During progression of melanoma, malignant melanocytes can be reprogrammed into mesenchymal-like cells through a process similar to epithelial-mesenchymal transition (EMT), which is associated with downregulation of the junctional protein E-cadherin and acquisition of a migratory phenotype....

  • Lights and Shadows in the Use of Mesenchymal Stem Cells in Lung Inflammation, a Poorly Investigated Topic in Cystic Fibrosis. Caretti, Anna; Peli, Valeria; Colombo, Michela; Zulueta, Aida // Cells (2073-4409);Jan2020, Vol. 9 Issue 1, p1 

    Mesenchymal stem cells (MSCs) are multipotent non-hematopoietic stem cells residing in many tissues, including the lung. MSCs have long been regarded as a promising tool for cell-based therapy because of their ability to replace damaged tissue by differentiating into the resident cell and...

  • Age-Related Characteristics of Multipotent Human Nasal Inferior Turbinate-Derived Mesenchymal Stem Cells. Hwang, Se Hwan; Park, Sun Hwa; Choi, Jin; Lee, Dong Chang; Oh, Jeong Hoon; Yeo, Un Cheol; Kim, Sung Won; Sun, Dong Il // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Background and Objectives: Multipotent mesenchymal stem cells (MSCs) represent a promising cell-based therapy for a number of degenerative conditions. Understanding the effect of aging on MSCs is crucial for both autologous therapy development and allogenic donors in older subjects whom...

  • CORRECTION: Proliferation and multi-differentiation potentials of human mesenchymal stem cells on thermoresponsive PDMS surfaces grafted with PNIPAAm. Dongyan SHI; Dan MA; Feiqing DONG; Chen ZONG; Liyue LIU; Dan SHEN; Wenji YUAN; Xiangmin TONG; Hengwu CHEN; Jinfu WANG // Bioscience Reports;Dec2010, Vol. 30 Issue 6, p455 

    A correction to the article "Proliferation and multi-differentiation potentials of human mesenchymal stem cells on thermoresponsive PDMS surfaces grafted with PNIPAAm," by Dongyan Shi and colleagues in the 30th volume of the "Bioscience Reports" journal is presented.

  • Erratum.  // Cellular Physiology & Biochemistry (Karger AG);Oct2017, Vol. 42 Issue 3, p1275 

    A correction to the article "MiR-495 Promotes Senescence of Mesenchymal Stem Cells by Targeting Bmi-1," by Lin et al, that was published in a 2017 issue is presented.

  • Neurorestoration Induced by Mesenchymal Stem Cells: Potential Therapeutic Mechanisms for Clinical Trials. Jung Hwa Seo; Sung.-Rae Cho // Yonsei Medical Journal;Nov2012, Vol. 53 Issue 6, p1059 

    Stem cells are emerging as therapeutic candidates in a variety of diseases because of their multipotent capacities. Among these, mesenchymal stem cells (MSCs) derived from bone marrow, umbilical cord blood or adipose tissue, comprise a population of cells that exhibit extensive proliferative...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics